Liminatus Pharma (LIMN) Current Assets (2024 - 2026)

Liminatus Pharma (LIMN) posted Current Assets of $2.8 million for Q1 2026, up 455.07% sequentially from $500574.0 in Q4 2025.

Liminatus Pharma (LIMN) Current Assets (2024 - 2026) Analysis & Trends

Liminatus Pharma has reported Current Assets for 3 years, with the latest figure at $2.8 million in Q1 2026.

Quarterly Current Assets changed N/A year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (changed N/A YoY) and the FY2025 annual result came in at $500574.0, down 90.52% from the prior year.
Current Assets grew to $2.8 million in Q1 2026 per LIMN's latest filing, from $500574.0 in the prior quarter.
Over five years, Current Assets peaked at $5.3 million in Q4 2024 and troughed at $500574.0 in Q4 2025.
A 3-year average of $2.3 million and a median of $1.8 million in 2025 frame the typical range for Current Assets.
The widest YoY moves for Current Assets: up 90.52% in 2025, down 90.52% in 2025.
Over 3 years, Current Assets stood at $5.3 million in 2024, then tumbled by 90.52% to $500574.0 in 2025, then jumped by 455.07% to $2.8 million in 2026.
According to Business Quant data, Current Assets over the past three periods registered $2.8 million, $500574.0, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn	12.54 Bn
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn	18.45 Bn
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn	8.07 Bn
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn	5.82 Bn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn	7.22 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	4.62 Bn
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn	18.80 Bn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.63 Bn
9	Royalty Pharma	27.30 Bn	26.46 Bn	-	1.76 Bn
10	Liminatus Pharma	265.71 Mn	265.71 Mn	-	3.39 Mn

Download Data